Ancillary Genetic Study to the Losartan vs. Atenolol Trail in Marfan Patients

The Pediatric Heart Network and the National Marfan Foundation are conducting a primary research study that compares Losartan to the beta-blocker Atenolol.

The Ancillary Genetic study will be conducted within the larger trial to investigate the role of genetic factors in determining responses to both Atenolol and Losartan.   Therefore, a pre-requisite for being in this ancillary study is that one must also be a participant in the Atenolol vs. Losartan clinical trial.   The results have the potential to benefit the Marfan community by identifying patients highly likely to respond (or not) to specific interventions.   Multiple centers across the United States and Belgium are participating in the study.

For more information, please click here.